Pregabalin Capsule
Product Images NDC 60760-750

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-750). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60760-750 (Pregabalin 60760 750 60)

Pregabalin Capsules 50 mg label showing package quantity of 60 capsules. The label includes the NDC 60760-750-60, manufacturing information from MSN Laboratories Private Limited in India, and packaging details by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. The label also includes storage instructions and a barcode with associated codes.*

FDA Label Image

Equation (Pregabain Gault Equation)

Mathematical formula for calculating creatinine clearance (CLCr) based on age in years, weight in kilograms, serum creatinine in mg/dL, with an adjustment factor for female patients. The formula is shown as a fraction with specific variables and constants.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for different Pregabalin dosages and placebo. The graph includes curves for Pregabalin 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo, illustrating their relative effectiveness in pain improvement.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A chart depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg taken three times a day compared to placebo. The graph shows two lines: a dashed line representing Pregabalin and a dotted line for placebo, with percentages on the vertical axis and percent pain improvement on the horizontal axis.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. Four lines represent different treatment groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo. The graph trends downward as percent improvement in pain increases, indicating patient improvement distribution across doses and placebo.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A line chart showing the percent of patients improved by percent improvement in pain from baseline for Pregabalin at 200 mg and 100 mg three times a day compared to placebo. The vertical axis represents the percent of patients improved (0-100%), and the horizontal axis represents percent improvement in pain from baseline (0-100%). Three lines correspond to Pregabalin 200 mg, Pregabalin 100 mg, and placebo, illustrating the distribution of patient improvement levels.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

Kaplan-Meier curve showing percent of patients improved versus percent improvement in pain from baseline comparing Pregabalin 50 mg and 100 mg taken three times a day against placebo. The graph uses distinct line styles for each group, illustrating patient response distributions over various pain improvement thresholds.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar graph showing responder rates (%) from two clinical studies (Study E1 and Study E3) for Pregabalin at various dosages compared to placebo. Study E1 includes placebo, 50 mg/day BID, 150 mg/day BID, 300 mg/day BID, and 600 mg/day BID, while Study E3 shows placebo, 600 mg/day BID, and 600 mg/day TID doses. The graph highlights statistically significant differences versus placebo.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line graph showing seizure reduction as median percentage change from baseline versus Pregabalin dose in mg/day. Four datasets are plotted: Stukly E1BID, E2BID, E3BID, and E3TID, each represented by different symbols. Seizure reduction increases with dose, with p-values indicating statistical significance at various points.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A line chart showing the relationship between percent improvement in pain from baseline (x-axis) and percent of patients improved (y-axis) for Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg compared with placebo. The chart includes four lines representing placebo and three Pregabalin dose groups.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve depicting the estimated percentage of subjects without LTR (loss to response) over 180 days for Pregabalin and placebo groups. The y-axis shows the estimated percentage without LTR from 0% to 100%, and the x-axis indicates days from 0 to 180. Solid and dashed lines represent Pregabalin and placebo groups, respectively.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved over a range of improvement percentages from baseline to Week 12 using BOCF. It shows two lines representing Pregabalin and Placebo groups, with the Pregabalin group having a consistently higher percentage of subjects improved than the Placebo group across the improvement scale.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A cumulative distribution graph comparing the percent of subjects improved on Pregabalin versus Placebo. The x-axis represents percent improvement from baseline to week 16 using BOCF, and the y-axis shows percent of subjects improved. Two curves are shown: a solid line for Pregabalin and a dashed line for Placebo, indicating a higher percentage of improvement with Pregabalin across most values.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of pregabalin showing its molecular arrangement with labeled functional groups, including an amino group and a carboxylic acid group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.